Cargando…

Ischaemia-free liver transplantation in humans: a first-in-human trial

Background Ischaemia-reperfusion injury is considered an inevitable component of organ transplantation, compromising organ quality and outcomes. Although several treatments have been proposed, none has avoided graft ischaemia and its detrimental consequences. Methods Ischaemia-free liver transplanta...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Zhiyong, Zhao, Qiang, Huang, Shanzhou, Huang, Changjun, Wang, Dongping, Yang, Lu, Zhang, Jian, Chen, Maogen, Wu, Linwei, Zhang, Zhiheng, Zhu, Zebin, Wang, Linhe, Zhu, Caihui, Zhang, Yixi, Tang, Yunhua, Sun, Chengjun, Xiong, Wei, Shen, Yuekun, Chen, Xiaoxiang, Xu, Jinghong, Wang, Tielong, Ma, Yi, Hu, Anbin, Chen, Yinghua, Zhu, Xiaofeng, Rong, Jian, Cai, Changjie, Gong, Fengqiu, Guan, Xiangdong, Huang, Wenqi, Ko, Dicken Shiu-Chung, Li, Xianchang, Tullius, Stefan G, Huang, Jiefu, Ju, Weiqiang, He, Xiaoshun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406025/
https://www.ncbi.nlm.nih.gov/pubmed/34590063
http://dx.doi.org/10.1016/j.lanwpc.2021.100260
_version_ 1783746439054098432
author Guo, Zhiyong
Zhao, Qiang
Huang, Shanzhou
Huang, Changjun
Wang, Dongping
Yang, Lu
Zhang, Jian
Chen, Maogen
Wu, Linwei
Zhang, Zhiheng
Zhu, Zebin
Wang, Linhe
Zhu, Caihui
Zhang, Yixi
Tang, Yunhua
Sun, Chengjun
Xiong, Wei
Shen, Yuekun
Chen, Xiaoxiang
Xu, Jinghong
Wang, Tielong
Ma, Yi
Hu, Anbin
Chen, Yinghua
Zhu, Xiaofeng
Rong, Jian
Cai, Changjie
Gong, Fengqiu
Guan, Xiangdong
Huang, Wenqi
Ko, Dicken Shiu-Chung
Li, Xianchang
Tullius, Stefan G
Huang, Jiefu
Ju, Weiqiang
He, Xiaoshun
author_facet Guo, Zhiyong
Zhao, Qiang
Huang, Shanzhou
Huang, Changjun
Wang, Dongping
Yang, Lu
Zhang, Jian
Chen, Maogen
Wu, Linwei
Zhang, Zhiheng
Zhu, Zebin
Wang, Linhe
Zhu, Caihui
Zhang, Yixi
Tang, Yunhua
Sun, Chengjun
Xiong, Wei
Shen, Yuekun
Chen, Xiaoxiang
Xu, Jinghong
Wang, Tielong
Ma, Yi
Hu, Anbin
Chen, Yinghua
Zhu, Xiaofeng
Rong, Jian
Cai, Changjie
Gong, Fengqiu
Guan, Xiangdong
Huang, Wenqi
Ko, Dicken Shiu-Chung
Li, Xianchang
Tullius, Stefan G
Huang, Jiefu
Ju, Weiqiang
He, Xiaoshun
author_sort Guo, Zhiyong
collection PubMed
description Background Ischaemia-reperfusion injury is considered an inevitable component of organ transplantation, compromising organ quality and outcomes. Although several treatments have been proposed, none has avoided graft ischaemia and its detrimental consequences. Methods Ischaemia-free liver transplantation (IFLT) comprises surgical techniques enabling continuous oxygenated blood supply to the liver of brain-dead donor during procurement, preservation, and implantation using normothermic machine perfusion technology. In this non-randomised study, 38 donor livers were transplanted using IFLT and compared to 130 conventional liver transplants (CLT). Findings Two recipients (5•3%) in the IFLT group experienced early allograft dysfunction, compared to 50•0% in patients receiving conventional transplants (absolute risk difference, 44•8%; 95% confidence interval, 33•6-55•9%). Recipients of IFLT had significantly reduced median (IQR) peak aspartate aminotransferase levels within the first week compared to CLT recipients (365, 238-697 vs 1445, 791-3244 U/L, p<0•001); likewise, median total bilirubin levels on day 7 were significantly lower (2•34, 1•39-4•09 mg/dL) in the IFLT group than in the CLT group (5•10, 1•90-11•65 mg/dL) (p<0•001). Moreover, IFLT recipients had a shorter median intensive care unit stay (1•48, 0•75-2•00 vs 1•81, 1•00-4•58 days, p=0•006). Both one-month recipient (97•4% vs 90•8%, p=0•302) and graft survival (97.4% vs 90•0%, p=0•195) were better for IFLT than CLT, albeit differences were not statistically significant. Subgroup analysis showed that the extended criteria donor livers transplanted using the IFLT technique yielded faster post-transplant recovery than did the standard criteria donor livers transplanted using the conventional approach. Interpretation IFLT provides a novel approach that may improve outcomes, and allow the successful utilisation of extended criteria livers. Funding This study was funded by National Natural Science Foundation of China, Guangdong Provincial Key Laboratory Construction Projection on Organ Donation and Transplant Immunology, and Guangdong Provincial international Cooperation Base of Science and Technology. Panel: Research in context
format Online
Article
Text
id pubmed-8406025
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-84060252021-09-28 Ischaemia-free liver transplantation in humans: a first-in-human trial Guo, Zhiyong Zhao, Qiang Huang, Shanzhou Huang, Changjun Wang, Dongping Yang, Lu Zhang, Jian Chen, Maogen Wu, Linwei Zhang, Zhiheng Zhu, Zebin Wang, Linhe Zhu, Caihui Zhang, Yixi Tang, Yunhua Sun, Chengjun Xiong, Wei Shen, Yuekun Chen, Xiaoxiang Xu, Jinghong Wang, Tielong Ma, Yi Hu, Anbin Chen, Yinghua Zhu, Xiaofeng Rong, Jian Cai, Changjie Gong, Fengqiu Guan, Xiangdong Huang, Wenqi Ko, Dicken Shiu-Chung Li, Xianchang Tullius, Stefan G Huang, Jiefu Ju, Weiqiang He, Xiaoshun Lancet Reg Health West Pac Research Paper Background Ischaemia-reperfusion injury is considered an inevitable component of organ transplantation, compromising organ quality and outcomes. Although several treatments have been proposed, none has avoided graft ischaemia and its detrimental consequences. Methods Ischaemia-free liver transplantation (IFLT) comprises surgical techniques enabling continuous oxygenated blood supply to the liver of brain-dead donor during procurement, preservation, and implantation using normothermic machine perfusion technology. In this non-randomised study, 38 donor livers were transplanted using IFLT and compared to 130 conventional liver transplants (CLT). Findings Two recipients (5•3%) in the IFLT group experienced early allograft dysfunction, compared to 50•0% in patients receiving conventional transplants (absolute risk difference, 44•8%; 95% confidence interval, 33•6-55•9%). Recipients of IFLT had significantly reduced median (IQR) peak aspartate aminotransferase levels within the first week compared to CLT recipients (365, 238-697 vs 1445, 791-3244 U/L, p<0•001); likewise, median total bilirubin levels on day 7 were significantly lower (2•34, 1•39-4•09 mg/dL) in the IFLT group than in the CLT group (5•10, 1•90-11•65 mg/dL) (p<0•001). Moreover, IFLT recipients had a shorter median intensive care unit stay (1•48, 0•75-2•00 vs 1•81, 1•00-4•58 days, p=0•006). Both one-month recipient (97•4% vs 90•8%, p=0•302) and graft survival (97.4% vs 90•0%, p=0•195) were better for IFLT than CLT, albeit differences were not statistically significant. Subgroup analysis showed that the extended criteria donor livers transplanted using the IFLT technique yielded faster post-transplant recovery than did the standard criteria donor livers transplanted using the conventional approach. Interpretation IFLT provides a novel approach that may improve outcomes, and allow the successful utilisation of extended criteria livers. Funding This study was funded by National Natural Science Foundation of China, Guangdong Provincial Key Laboratory Construction Projection on Organ Donation and Transplant Immunology, and Guangdong Provincial international Cooperation Base of Science and Technology. Panel: Research in context Elsevier 2021-08-26 /pmc/articles/PMC8406025/ /pubmed/34590063 http://dx.doi.org/10.1016/j.lanwpc.2021.100260 Text en © 2021 The Author(s). Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Guo, Zhiyong
Zhao, Qiang
Huang, Shanzhou
Huang, Changjun
Wang, Dongping
Yang, Lu
Zhang, Jian
Chen, Maogen
Wu, Linwei
Zhang, Zhiheng
Zhu, Zebin
Wang, Linhe
Zhu, Caihui
Zhang, Yixi
Tang, Yunhua
Sun, Chengjun
Xiong, Wei
Shen, Yuekun
Chen, Xiaoxiang
Xu, Jinghong
Wang, Tielong
Ma, Yi
Hu, Anbin
Chen, Yinghua
Zhu, Xiaofeng
Rong, Jian
Cai, Changjie
Gong, Fengqiu
Guan, Xiangdong
Huang, Wenqi
Ko, Dicken Shiu-Chung
Li, Xianchang
Tullius, Stefan G
Huang, Jiefu
Ju, Weiqiang
He, Xiaoshun
Ischaemia-free liver transplantation in humans: a first-in-human trial
title Ischaemia-free liver transplantation in humans: a first-in-human trial
title_full Ischaemia-free liver transplantation in humans: a first-in-human trial
title_fullStr Ischaemia-free liver transplantation in humans: a first-in-human trial
title_full_unstemmed Ischaemia-free liver transplantation in humans: a first-in-human trial
title_short Ischaemia-free liver transplantation in humans: a first-in-human trial
title_sort ischaemia-free liver transplantation in humans: a first-in-human trial
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406025/
https://www.ncbi.nlm.nih.gov/pubmed/34590063
http://dx.doi.org/10.1016/j.lanwpc.2021.100260
work_keys_str_mv AT guozhiyong ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT zhaoqiang ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT huangshanzhou ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT huangchangjun ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT wangdongping ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT yanglu ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT zhangjian ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT chenmaogen ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT wulinwei ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT zhangzhiheng ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT zhuzebin ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT wanglinhe ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT zhucaihui ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT zhangyixi ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT tangyunhua ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT sunchengjun ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT xiongwei ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT shenyuekun ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT chenxiaoxiang ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT xujinghong ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT wangtielong ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT mayi ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT huanbin ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT chenyinghua ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT zhuxiaofeng ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT rongjian ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT caichangjie ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT gongfengqiu ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT guanxiangdong ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT huangwenqi ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT kodickenshiuchung ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT lixianchang ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT tulliusstefang ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT huangjiefu ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT juweiqiang ischaemiafreelivertransplantationinhumansafirstinhumantrial
AT hexiaoshun ischaemiafreelivertransplantationinhumansafirstinhumantrial